Category: Hot Mandates

Hot Investor Mandate 1: Newly Founded Family Office Actively Seeking Early-Stage Life Science Investments, from Pre-Clinical Stage Assets to Medical Devices

~ Next Phase Admin ~ Leave a comment

A newly formed Delaware family office investment vehicle representing East Coast-based family interests is looking to invest in ground-breaking life science and medical device technologies. While the firm is very flexible in terms of investment size, they are generally looking to invest a minimum of $0.5 million per round. The firm is open to Investing in companies located throughout North America and Europe.

The firm is looking for breakthrough technologies with a strong social ethos in the Therapeutics, Medical Device and Diagnostics Sectors that address underserved medical needs, or provide innovative and disruptive approaches to common medical procedures and treatments. The firm invests on an opportunistic basis and are especially interested in areas of intersecting technologies, such as nucleic acid-based drugs and delivery, regenerative medicine and cell- based therapeutics.

The firm is less interested in small molecules and generally will not consider biosimilars or other technologies for which there is already multiple therapeutic options. The firm is looking for niche disease areas where disruptive therapeutics have the potential to be truly disease- modifying, not just provide symptomatic relief or palliative care. The firm typically is interested in preclinical stage assets that have well-developed animal model dossiers to Phase II or early Phase III stage assets. The firm’s investment mandate particularly focuses on “smart” clinical trial formats such as adaptive trials and Master Protocol trials for capital efficiency.

For devices, the firm is looking for devices that address and perhaps substitute for a pharmacologic in a given therapeutic market, such as deep brain stimulation technologies and orthopedics. The firm is generally not interested in cardiovascular disease or diabetes.

The firm is currently reviewing co-investment opportunities in private companies and on an opportunistic basis, considering investment in micro-and small-cap public companies as a direct investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 2: Chinese Government Partnered VC Firm Invests in Therapeutics and Clinical Testing Companies, with Focus on China Angle

~ Next Phase Admin ~ Leave a comment

A venture capital firm partnered with the Chinese Government was founded in 2016, and focuses on cross-border investments. When investing, the firm doesn’t only provide financial capital, they also provide their global consulting services focused specifically on helping companies work across borders and in China. With the Chinese Government partnership, the firm seeks to bring good projects from North America to China and are focused on technologies that are at an advanced stage with patents that are willing to launch in Chinese markets or to set up factories and labs in China. The firm is however, willing to invest smaller amounts in good opportunities that have no interest/fit for the Chinese markets as well. The firm’s major focus within the life sciences is biotech and is focused on seed to series B rounds. The firm generally invests up to $10M USD for Series A deals, is flexible for series B rounds, and invests up to $1M USD for seed stage rounds.

Within the Life Sciences space, the firm is specifically focused on clinical tests, therapeutics, and other biotech technologies. The firm is also willing to look at medical devices to a small degree but is not very familiar with those technologies. Additionally, the firm is focused on technologies within these sectors that have a good fit with the Chinese Market or have a strong interest in working in China.

When investing, the firm looks to take a board seat. The firm provides consulting, localization services, and the ability to leverage resources in China to help the company grow alongside their direct equity investment and believe that these abilities can be best leveraged with a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 3: Investment Arm of Major China Genomics Company Looks for Complementary Early-Stage Genomics & Big Data/AI Technologies

~ Next Phase Admin ~ Leave a comment

A branch of a subsidiary of a major genomics sequencing company in China is actively seeking technologies from the US, Canada, and China that will complement what they currently have. In addition to direct investments, the firm often functions as a strategic partner that can help provide a technology platform for a startup or even integrate the new technology into their system. The firm also provides access to their large marketing team once the product is developed to help the startup during their commercialization phase. The firm is currently interested in early stage companies: usually at seed to series A and is rather flexible as to the financing terms. Additionally, the firm is willing to work through either partnerships or direct investments.

The firm is actively seeking new genomics technologies. Currently, the firm is interested in any technology within diagnostics, digital health, and medtech that has a focus on genomics. Within the diagnostics and medtech sectors, the firm is particularly interested in sequencing technologies currently, but is willing to see all early stage genomics-based technologies within these sectors. For digital health, the firm is interested in companies involved in big data and AI that already have algorithms that can utilize the large pool of genomics data that the firm currently has access to.

When investing, the firm likes to take an active role in the company and prefers taking board seats but does not require a board seat. Otherwise, the firm prefers to work with companies that the firm can work with and help develop into either a potential integration or a productive partnership.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 4: Canada-Based Private Investment Firm Invests Opportunistically in Early-Stage Life Science & Healthcare Companies

~ Next Phase Admin ~ Leave a comment

A Canada-based private social venture capital firm invests in early-stage companies, and is currently interested in new developments in the healthtech and biotech sectors. The firm is open to exploring a wide range of opportunities. The founder of the firm is an accomplished investor of 20+ years with a track record of scaling successful businesses, mostly in the technology sectors. The founder has also established a foundation to support the growth and activities of organizations dedicated to developing innovative, system-changing solutions with high potential for global impact. With both initiatives, the founder has been actively working with like-minded companies and funds in Canada.

The firm’s initial investments are generally in the $100-500K range with a few exceptions. Their geographical focus lies in North America and all investments have been based in USA and Canada, but the firm is open to considering global opportunities.

The firm has broad interests in life sciences and is open to considering all early-stage opportunities in therapeutics, medical devices, diagnostics, and healthcare IT. The firm is particularly interested in preventative/proactive technologies that can significantly benefit health management.

The firm does not have specific management team requirements but prefers to see teams with a successful track record and relevant expertise. The firm generally does not lead investment rounds or seek board representation.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 1: Chinese Cross-Border VC Invests Up to $30M in Both Pre-Revenue and Revenue-Generating Life Science Companies

~ Next Phase Admin ~ Leave a comment

A global venture capital firm founded in 1995 has offices in the Silicon Valley area and China. The firm recently closed a $750 million fund as well as a smaller $150 million fund. The firm invests exclusively in the life science sector and invests primarily in the USA and China, but will also invest in other regions such as Europe and Canada. Within China, the firm makes growth investments in companies that have existing revenues; in the USA and other regions, the firm makes both venture and growth-equity stage investments in both pre-revenue and revenue-stage companies. The firm’s allocations are highly varied. From the main fund, investments typically range from $10-30m, though larger investments are of interest as well; the firm’s smaller fund makes investments of typically $2-5 million, generally in financing rounds of $10 million or less. The firm is open to syndication. The firm is also particularly interested in working with companies that are open to or actively interested in seeking partnerships or opportunities in China.

The firm invests in therapeutics, medical devices, diagnostics, healthcare services, and clinically-oriented healthcare IT, and will consider investing in any indication area or technology subsector; however, orphan indications, dermatology/aesthetics, oncology, and blood diseases are of particular interest in the biopharma space; general surgery, neurovascular, cardiovascular, minimally invasive technologies, women’s health, respiratory care, novel diagnostics and orthopedics are of particular interest in the device space. The smaller fund focuses on early stage opportunities in biotech; from the main fund, the firm in most cases makes investments in products that have obtained market approval or are very close to commercialization, but earlier investments may be considered for highly innovative products or products that can demonstrate strong efficacy signals at an earlier stage (such as anti-infectives). For devices and diagnostics, the firm only invests in commercial-stage companies. Generally, the firm does not invest in imaging.

The firm is flexible regarding management teams, and works with both serial entrepreneurs and entrepreneurs who lack industry experience. In addition to investing in private companies, The firm is able to invest in public companies by means of PIPEs or public market placements. The firm is interested in investing in companies with products that can demonstrate cost-effectiveness.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 2: Corporate Venture Arm of Large Medtech Company Seek to Invest and Partner with Medical Device Companies in Cardiovascular, Diabetes, Among Other Indications

~ Next Phase Admin ~ Leave a comment

A corporate investment group invests strategically on behalf of a large medical technology corporate. The firm uses a variety of structures to work with early stage medical technology companies, including both licensing relationships and equity investments on a case by case basis. The firm is a flexible investor, and the firm’s allocation sizes are wide ranging. The firm invests worldwide.

The firm invests in sectors that are relevant to the corporate’s business groups – areas of interests include cardiovascular, diabetes, restorative therapies, and minimally invasive therapies. This includes interests in spinal implants, neuromodulation treatments for pain and urological disorders, deep brain stimulation, neurovascular devices, general surgery, gastrointestinal care, pulmonology, respiratory care and monitoring technologies, etc. The firm is interested in diversifying the corporate’s product and services offerings within all of these areas of interests and also in integrating new fields of information technology and services into the strategic areas, such as IT-enabled patient monitoring and contract management of provider facilities. The firm invests at a range of development stages but generally prefers to work with companies that have obtained clinical data regarding their asset.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 3: Canada Based VC Invests in Early-Stage Medtech and Digital Health Companies in North America

~ Next Phase Admin ~ Leave a comment

A Canada-based investment firm that was founded in 2000 has two Health Tech Venture funds that invested in a total of 26 companies, mostly in Canada. The firm is currently in the process of raising its third fund. The firm invests in the health technology sector, especially medical technology and digital health. The second fund focuses on pre and post Series A investments with the ability to do follow-on funding. The investment size can range from $100K to over $1M and up to $2-4M with follow-on funding. The capital structure is flexible, especially as they are currently raising their third fund. The firm typically co-invests and will lead investments depending on the occasion and size of the round. Investment can be in form of equity, whereas convertible loan and other capital structures will be considered. The new fund looks to invest in 10-20 companies. The firm focuses on companies based in Canada, but it will also look at opportunities in the US. The firm’s investment activity has catalyzed over $200M of investment in the Canadian venture capital space.

In the life sciences, the firm is currently looking for new investments in the medical technology, diagnostics, digital health, AI applications in healthcare, surgical robotics and healthcare IT sectors with a particular interest in medical devices with a software component. The firm is interested in all classes of medical devices and is indication agnostic. The firm is focused on preclinical to clinical stage technology and is focused on technology that requires an FDA regulatory pathway. The firm will consider therapeutics companies from time-to-time, however, therapeutics is not the firm’s focus. Historically, the firm was active in a company developing blood-testing platform for infectious diseases.

The firm focuses on investments in private companies with an experienced management team and growth potential. The firm will take a board seat based on case-by-case basis, though is not the requirement.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.